Stephen Mitchener joined Karyopharm in December 2020 and is responsible for setting the partnering and business strategy for the development and commercialization of all Karyopharm clinical and commercial programs.
Prior to joining Karyopharm, Stephen served as Chief Business Officer and Head, Strategic Finance, and spearheaded all commercial, financing, partnering, and corporate development initiatives at Axcella Healthcare. Before joining Axcella Healthcare in 2018, Dr. Mitchener spent 15 years at Novartis in roles of increasing responsibility, in both U.S. and international roles within its Oncology Business. As Head of Strategy, Partnering and Operations, Dr. Mitchener was responsible for leading U.S. oncology strategy, enterprise operations, non-core brands and partnering activities. During his tenure at Novartis, he also held various commercial, medical and business development roles, including Business Franchise Head, Oncology, Global Pharma Strategy Director, and Global New Product Director. Dr. Mitchener was involved in securing partnerships in oncology with multiple Big Pharma, technology, academic and healthcare partners. Stephen has over seventeen years of partnering and corporate development experience within the biopharmaceutical industry.
Stephen received a PharmD from the University of North Carolina at Chapel Hill.
What is Stephen Mitchener's net worth?
The estimated net worth of Stephen Mitchener is at least $81,478.76 as of March 1st, 2023. Mr. Mitchener owns 128,313 shares of Karyopharm Therapeutics stock worth more than $81,479 as of December 21st. This net worth approximation does not reflect any other investments that Mr. Mitchener may own. Learn More about Stephen Mitchener's net worth.
How do I contact Stephen Mitchener?
Has Stephen Mitchener been buying or selling shares of Karyopharm Therapeutics?
Stephen Mitchener has not been actively trading shares of Karyopharm Therapeutics during the past quarter. Most recently, Stephen Mitchener sold 6,357 shares of the business's stock in a transaction on Wednesday, March 1st. The shares were sold at an average price of $3.03, for a transaction totalling $19,261.71. Following the completion of the sale, the senior vice president now directly owns 128,313 shares of the company's stock, valued at $388,788.39. Learn More on Stephen Mitchener's trading history.
Who are Karyopharm Therapeutics' active insiders?
Are insiders buying or selling shares of Karyopharm Therapeutics?
During the last twelve months, insiders at the sold shares 23 times. They sold a total of 1,461,709 shares worth more than $1,454,603.97. The most recent insider tranaction occured on October, 4th when CEO Richard A Paulson sold 3,607 shares worth more than $3,174.16. Insiders at Karyopharm Therapeutics own 4.3% of the company.
Learn More about insider trades at Karyopharm Therapeutics. Information on this page was last updated on 10/4/2024.
